Thursday, March 10, 2011

FDA & Justice Dept files consent decree against JNJ (NYSE: JNJ) division McNeil-PPC

The FDA today announced that a consent decree of permanent injunction has been filed against Tylenol producer McNeil-PPC (division of JNJ), for failing to comply with good manufacturing practices.

The FDA will assume control of three plants; located in Puerto Rico, Fort Washington, PA and Lancaster, PA.

The FDA announcement can be found here:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246685.htm


Excerpt:

"Manufacturing deficiencies at McNeil’s facilities have resulted in several extensive recalls, including an April 30, 2010, recall of lots of several liquid products such as children’s Tylenol, Motrin, Zyrtec, and Benadryl products. In January 2010, the FDA issued a Warning Letter to McNeil’s Consumer Healthcare Division regarding violations identified at McNeil’s Las Piedras facility.

The decree, filed by the U.S. Department of Justice’s Office of Consumer Litigation and the U.S. Attorney’s Office for the Eastern District of Pennsylvania, requires McNeil to destroy all drugs under McNeil’s control that have been recalled from the Fort Washington, Las Piedras, and Lancaster facilities since December 2009. McNeil also must retain an independent expert to inspect the Fort Washington, Las Piedras, and Lancaster facilities to determine whether the violations have been corrected, and to ensure that adequate manufacturing processes are in place. After expert certification, the FDA will determine if the facilities are in compliance.

If the defendants violate the decree, the FDA may order McNeil to cease manufacturing, recall products, and take other corrective action, including levying fines of $15,000 for each day and an additional $15,000 for each violation of the law, up to $10 million annually."

No comments:

Post a Comment